

# $\beta_2$ -Glycoprotein I inhibits von Willebrand factor–dependent aggregation

Blood

110, 1483-1491

DOI: [10.1182/blood-2006-10-053199](https://doi.org/10.1182/blood-2006-10-053199)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anti-β <sub>2</sub> glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2421-2428.	3.8	67
2	Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons. <i>Current Rheumatology Reports</i> , 2008, 10, 67-73.	4.7	32
3	Survey of the year 2007 commercial optical biosensor literature. <i>Journal of Molecular Recognition</i> , 2008, 21, 355-400.	2.1	153
4	Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. <i>Blood Reviews</i> , 2008, 22, 93-105.	5.7	74
6	Platelets and the antiphospholipid syndrome. <i>Lupus</i> , 2008, 17, 888-894.	1.6	47
7	Mechanisms of Disease: antiphospholipid antibodies—from clinical association to pathologic mechanism. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 192-199.	3.2	81
8	New developments in lupus-associated antiphospholipid syndrome. <i>Lupus</i> , 2008, 17, 443-446.	1.6	4
9	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 236-250.	2.7	205
10	Novel therapies for the antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 193-203.	3.0	1
12	Anti-Endothelial Antibodies Interfere in Apoptotic Cell Clearance and Promote Thrombosis in Patients with Antiphospholipid Syndrome. <i>Journal of Immunology</i> , 2009, 182, 1756-1762.	0.8	20
15	Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during hemodialysis. <i>Kidney International</i> , 2009, 76, 404-413.	5.2	69
16	Antiphospholipid antibodies: Paradigm in transition. <i>Journal of Neuroinflammation</i> , 2009, 6, 3.	7.2	37
17	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 55-67.	0.1	4
18	Pathogenesis and management of antiphospholipid syndrome. <i>Thrombosis Research</i> , 2009, 123, S4-S9.	1.7	3
19	Association between beta <sub>2</sub> -glycoprotein I plasma levels and the risk of myocardial infarction in older men. <i>Blood</i> , 2009, 114, 3656-3661.	1.4	33
20	Regulation of von Willebrand factor-platelet interactions. <i>Thrombosis and Haemostasis</i> , 2010, 104, 449-455.	3.4	57
21	Anti-β <sub>2</sub> glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. <i>Journal of Reproductive Immunology</i> , 2010, 84, 95-99.	1.9	17
22	Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of β <sub>2</sub> -glycoprotein I. <i>Protein Science</i> , 2010, 19, 1065-1078.	7.6	23

#	ARTICLE	IF	CITATIONS
23	Redox control of Î²2â€glycoproteinÎ” von Willebrand factor interaction by thioredoxinâ€1. Journal of Thrombosis and Haemostasis, 2010, 8, 1754-1762.	3.8	52
24	Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. European Journal of Clinical Investigation, 2010, 40, 451-464.	3.4	41
25	Pathophysiological mechanisms in antiphospholipid syndrome. International Journal of Clinical Rheumatology, 2011, 6, 157-171.	0.3	22
27	Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS). , 2011, , .		1
28	Î²2-Glycoprotein I: a novel component of innate immunity. Blood, 2011, 117, 6939-6947.	1.4	101
30	Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine, 2011, 270, 110-122.	6.0	91
31	Î²2â€GlycoproteinÎ”: evolution, structure and function. Journal of Thrombosis and Haemostasis, 2011, 9, 1275-1284.	3.8	180
32	Molecular pathophysiology of theâ€antiphospholipid syndrome: the role of oxidative postâ€translational modification of beta 2 glycoprotein I. Journal of Thrombosis and Haemostasis, 2011, 9, 275-282.	3.8	56
33	New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I. Current Rheumatology Reports, 2011, 13, 90-95.	4.7	27
35	The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. Lupus, 2011, 20, 5-13.	1.6	78
36	Thrombotic Microangiopathic Hemolytic Anemia With Reduction of ADAMTS13 Activity. American Journal of Clinical Pathology, 2011, 135, 406-416.	0.7	24
38	Antiphospholipid-Related Chorea. Frontiers in Neurology, 2012, 3, 150.	2.4	47
39	Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor. Current Vascular Pharmacology, 2012, 10, 762-766.	1.7	6
40	Indications for a protective function of beta2â€glycoprotein <scp>I</scp> in thrombotic thrombocytopenic purpura. British Journal of Haematology, 2012, 159, 94-103.	2.5	5
41	Post-translational oxidative modification of Î²2-glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome. Autoimmunity Reviews, 2012, 11, 779-780.	5.8	10
42	von Willebrand factor: the old, the new and the unknown. Journal of Thrombosis and Haemostasis, 2012, 10, 2428-2437.	3.8	185
43	Regulating interactions between vonWillebrand factor and platelets. Hematologie, 2012, 18, 109-115.	0.0	0
44	Antiphospholipid syndrome: Laboratory testing and diagnostic strategies. American Journal of Hematology, 2012, 87, S75-81.	4.1	55

#	ARTICLE	IF	CITATIONS
45	von Willebrand factor: at the crossroads of bleeding and thrombosis. International Journal of Hematology, 2012, 95, 353-361.	1.6	36
46	Recent developments in our understanding of the antiphospholipid syndrome. International Journal of Laboratory Hematology, 2012, 34, 223-231.	1.3	26
48	Inherited Disorders of Platelets. Hematology/Oncology Clinics of North America, 2013, 27, 613-627.	2.2	13
49	Unwinding the von Willebrand factor strings puzzle. Blood, 2013, 121, 270-277.	1.4	123
50	Pathogenesis of the Nervous System. , 2013, , 363-367.		2
51	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 901-908.	3.4	37
52	Identification of APOH polymorphisms as common genetic risk factors for venous thrombosis in the Chinese population. Journal of Thrombosis and Haemostasis, 2014, 12, 1616-1625.	3.8	14
53	<i>S. aureus</i> proteins SSL6 and SEIX interact with neutrophil receptors as identified using secretome phage display. Cellular Microbiology, 2014, 16, 1646-1665.	2.1	30
54	A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: A practical guide. Nanotoxicology, 2014, 8, 220-232.	3.0	11
55	The role of Î²2-glycoprotein I (Î²2GPI) carbohydrate chains in the reactivity of anti-Î²2GPI antibodies from patients with primary antiphospholipid syndrome and in the activation and differentiation of U937 cells. Biochemical and Biophysical Research Communications, 2014, 453, 94-100.	2.1	4
56	Exploiting the kinetic interplay between GPIIb/IIIa-VWF binding interfaces to regulate hemostasis and thrombosis. Blood, 2014, 124, 3799-3807.	1.4	14
57	Thrombin generation in the presence of platelets is sensitive to the activation status of von Willebrand factor. Thrombosis and Haemostasis, 2015, 113, 209-211.	3.4	4
58	The antiphospholipid syndrome: still an enigma. Hematology American Society of Hematology Education Program, 2015, 2015, 53-60.	2.5	43
59	Of von Willebrand factor and platelets. Cellular and Molecular Life Sciences, 2015, 72, 307-326.	5.4	157
60	Identification of anti-moesin antibodies in the serums of patients with antiphospholipid syndrome. Thrombosis Research, 2015, 135, 867-872.	1.7	4
61	The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding. Thrombosis and Haemostasis, 2016, 116, 87-95.	3.4	9
62	Redox Status of Î²2GPI in Different Stages of Diabetic Angiopathy. Disease Markers, 2016, 2016, 1-7.	1.3	3
63	Î²2GPI, Anti-Î²2GPI Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome. Antibodies, 2016, 5, 12.	2.5	25

#	ARTICLE	IF	CITATIONS
64	Molecular mapping of $\beta$ -thrombin ( $\beta$ T)/ $\beta$ 2-glycoprotein I ( $\beta$ 2GPI) interaction reveals how $\beta$ 2GPI affects $\beta$ T functions. <i>Biochemical Journal</i> , 2016, 473, 4629-4650.	3.7	16
66	High-Flux Dialysis: Clinical, Biochemical, and Proteomic Comparison with Low-Flux Dialysis and On-Line Hemodiafiltration. <i>Blood Purification</i> , 2017, 44, 129-139.	1.8	9
67	Diagnosis and management of the antiphospholipid syndrome. <i>Blood Reviews</i> , 2017, 31, 406-417.	5.7	120
68	Thrombophilia Caused by Beta2-Glycoprotein I Deficiency: In Vitro Study of a Rare Mutation in APOH Gene. <i>Current Medical Science</i> , 2018, 38, 379-385.	1.8	6
69	Effects of anti- $\beta$ 2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 380-389.	2.3	10
70	Oxidative post-translational modification of $\beta$ 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome. <i>Free Radical Biology and Medicine</i> , 2018, 125, 98-103.	2.9	16
71	Extracellular Vesicles in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 493-504.	2.7	22
72	The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 458-465.	2.7	12
73	The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex. <i>Lupus</i> , 2018, 27, 319-326.	1.6	7
74	The interaction of $\beta$ 2-glycoprotein I with lysophosphatidic acid in platelet aggregation and blood clotting. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2018, 1866, 1232-1241.	2.3	3
75	Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. <i>Lupus</i> , 2019, 28, 1460-1467.	1.6	6
76	Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China. <i>Lupus</i> , 2019, 28, 1558-1565.	1.6	2
77	Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor. <i>PLoS ONE</i> , 2019, 14, e0211961.	2.5	18
78	Reduced $\beta$ 2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. <i>Science China Life Sciences</i> , 2019, 62, 921-929.	4.9	2
79	Cystathionine $\beta$ -synthase deficiency: different changes in proteomes of thrombosis-resistant <i>Cbs</i> <sup>+/+</sup> mice and thrombosis-prone <i>CBS</i> <sup>+/+</sup> humans. <i>Scientific Reports</i> , 2020, 10, 10726.	3.3	8
80	Molecular Mechanisms of Antiphospholipid Antibodies and Their Paradoxical Role in the Pathogenesis of Seronegative APS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8411.	4.1	21
81	Distinct and overlapping effects of $\beta$ 2-glycoprotein I conformational variants in ligand interactions and functional assays. <i>Journal of Immunological Methods</i> , 2020, 487, 112877.	1.4	4
82	Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1087-1110.	2.3	8

#	ARTICLE	IF	CITATIONS
83	The antiphospholipid syndrome may induce non-thrombotic internal jugular vein stenosis: two cases report. <i>BMC Neurology</i> , 2021, 21, 9.	1.8	3
84	Antiphospholipid-Syndrom bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-18.	0.0	0
85	VWF, Platelets and the Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4200.	4.1	13
86	An allosteric redox switch in domain V of $\beta$ 2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. <i>Journal of Biological Chemistry</i> , 2021, 297, 100890.	3.4	10
87	Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk. <i>Journal of Autoimmunity</i> , 2021, 122, 102675.	6.5	4
89	Thrombocytopenias: a clinical point of view. <i>Blood Transfusion</i> , 2009, 7, 75-85.	0.4	29
90	Decreased beta2-Glycoprotein I Plasma Levels as a Risk Factor for Myocardial Infarction in Men.. <i>Blood</i> , 2008, 112, 1813-1813.	1.4	17
91	Antiphospholipid Antibody Syndrome. , 2012, , 1641-1648.		0
92	Antiphospholipid Syndrome and Venous Thrombosis. , 0, , .		0
93	The Management of Antiphospholipid Antibodies Affected Pregnancy. , 0, , .		0
94	Natural Proteins Involved in Antiphospholipid Syndrome. , 2017, , 15-27.		1
95	$\beta$ 2-glycoprotein I exerts antithrombotic function through its domain V in mice. <i>Journal of Autoimmunity</i> , 2022, 126, 102747.	6.5	3
96	Pathophysiology of Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1085-1095.	3.4	7
97	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. <i>Seminars in Immunopathology</i> , 2022, 44, 347-362.	6.1	67
98	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 1603-1604.	5.6	0
100	The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210885.	1.7	19
102	Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
103	Role of $\beta$ 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome. <i>Rheumatology &amp; Autoimmunity</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
104	High prevalence of thrombophilic risk factors in patients with central retinal artery occlusion. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	4
105	Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease. <i>Biomedicines</i> , 2023, 11, 2814.	3.2	2
106	Anti-phospholipid autoantibodies in human diseases. <i>Clinical Immunology</i> , 2023, 256, 109803.	3.2	1
107	Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients. <i>Biomedicines</i> , 2023, 11, 3329.	3.2	0
108	Platelets and Thrombotic Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2024, 13, 741.	2.4	0